Spero Therapeutics, Inc. (NASDAQ:SPRO) is a clinical-stage biopharmaceutical company dedicated to developing novel therapies designed to address some of the most pressing challenges in infectious disease treatment. Founded with a mission to combat the growing global threat of antibiotic resistance, Spero has focused its research and development on advancing new options for patients suffering from multi-drug resistant bacterial infections and rare diseases where current treatment options are either inadequate or nonexistent. Based in Cambridge, Massachusetts, the company leverages deep scientific expertise and strategic collaborations with major industry players to accelerate the path of its therapies from clinical development toward commercialization.
At the core of Spero’s pipeline is tebipenem HBr, an oral carbapenem antibiotic that represents a groundbreaking innovation in the treatment of complicated urinary tract infections. Carbapenems are considered one of the most potent classes of antibiotics, but until now they have only been available in intravenous form, limiting patient access and creating costly hospital-based treatments. Spero’s tebipenem HBr, currently being developed in partnership with GSK, has already demonstrated strong Phase 3 clinical results, showing comparable efficacy to IV-administered standards of care. If approved, tebipenem would become the first oral carbapenem available to patients, representing a significant step forward in combating bacterial infections and offering a more convenient, cost-effective alternative to hospital-based therapies.
In addition to tebipenem HBr, Spero maintains a broader pipeline that reflects its long-term strategy of innovation in infectious disease. The company has worked to advance a portfolio of product candidates addressing rare and resistant infections, showcasing its dedication not only to addressing immediate market opportunities but also to building a foundation for sustainable growth. By targeting conditions with both high unmet medical need and significant commercial potential, Spero is positioning itself as a leader in redefining the standards of care in antimicrobial therapy.
Spero’s progress has been supported by key strategic and financial milestones, including partnerships with large pharmaceutical companies that provide validation of its science, milestone payments, and extended financial runway. Recent financial performance has shown improvements in operational efficiency, while ongoing collaborations ensure the company is well-capitalized to continue advancing its lead programs through late-stage development. With a strong management team, a clear clinical focus, and a mission-driven approach, Spero Therapeutics continues to build its reputation as a company capable of addressing some of the greatest challenges in modern medicine.
Spero Therapeutics: Oversold but Ready for a Powerful Comeback
Spero Therapeutics (NASDAQ: SPRO) has endured a rough stretch in the stock market, with shares down 17.7% over the last four weeks amid heavy selling pressure. While at first glance this decline may look discouraging, the bigger picture suggests that SPRO may be on the cusp of a major turnaround. The company, which is advancing innovative treatments for multi-drug resistant bacterial infections and rare diseases, continues to gain validation from both the clinical and financial sides of its business. Combined with technical signals pointing to a reversal and analysts raising their earnings expectations, Spero Therapeutics is emerging as one of the more intriguing small-cap biotech rebound stories of 2025.
CHECK THIS OUT: Saudi Arabia Wants CEL-SCI (CVM)’s Multikine Now! and Aligos Therapeutics (ALGS) Doubles Cash to $122.9M.
Technical Indicators Show SPRO is Deeply Oversold
One of the most reliable tools for identifying potential turning points in a stock is the Relative Strength Index (RSI), a momentum oscillator that measures the speed and change of price movements. SPRO’s RSI reading currently stands at 27.97, well below the commonly used oversold threshold of 30. When a stock enters oversold territory, it often signals that the selling pressure has become excessive and that a rebound may be approaching as the balance between supply and demand resets.
While technical indicators should never be used in isolation, the combination of sharp recent declines and an RSI below 30 strongly suggests that SPRO has been oversold and is positioned for a rebound. Investors who look for contrarian entry points often view such setups as opportunities to capture gains during the inevitable reversion to fair value.
Analyst Upgrades Strengthen the Case for a Turnaround
Beyond technical signals, the fundamentals are also pointing in a bullish direction. In the past 30 days, sell-side analysts covering SPRO have significantly raised their earnings per share (EPS) estimates, driving the consensus forecast higher by an impressive 44.8%. This kind of upward revision is rarely seen without underlying improvements in a company’s operations or revenue outlook, and historically, rising estimates tend to translate into stock price appreciation.
SPRO also holds a Zacks Rank #2 (Buy), placing it among the top 20% of more than 4,000 ranked stocks. This ranking system is based on earnings estimate revisions and EPS surprises, both of which are trending positively for Spero. With analysts aligning in their outlook and the company showing the ability to outperform expectations, the fundamentals support the idea that SPRO is ready to stage a comeback.
Tebipenem HBr: A Transformational Drug Candidate
At the heart of Spero’s pipeline is tebipenem HBr, a first-in-class oral carbapenem antibiotic being developed in partnership with GSK. This candidate recently achieved a milestone when its Phase 3 trial was halted early for efficacy, demonstrating that tebipenem was as effective as IV-administered imipenem-cilastatin in treating complicated urinary tract infections (cUTIs) in over 1,600 patients. The significance of this development cannot be overstated, as tebipenem HBr could become the first oral carbapenem approved for cUTIs, a condition affecting nearly 3 million Americans annually.
The commercial potential is massive. Oral administration would provide a more convenient, less costly, and equally effective alternative to intravenous therapies, addressing a huge unmet need in infectious disease treatment. If approved, tebipenem could fundamentally reshape the standard of care, positioning Spero as a leader in antibiotic innovation.
Financial Improvements Bolster Long-Term Outlook
Spero’s recent financial performance further supports a bullish stance. In its Q2 2025 results, the company reported an EPS loss of only –$0.03, dramatically better than analyst expectations of –$0.57, a positive surprise of 94.7%. Revenue also came in strong at $14.2 million, exceeding forecasts of $11 million, while research and development expenses were cut by more than half, declining from $23.7 million to $10.7 million.
These results indicate not only that Spero is operating more efficiently but also that its partnership with GSK is providing both financial and strategic support. With milestone payments and collaborations extending the company’s cash runway into 2028, the risk of near-term dilution has been significantly reduced—a common concern for small-cap biotech investors.
Valuation and Upside Potential
Despite the promising clinical and financial progress, SPRO shares trade at only $2.15, giving the company a market valuation that remains conservative compared to peers. Analysts covering the stock see an average price target of $7.83, representing a potential upside of more than 250% from current levels. When combined with the oversold technical setup, this upside becomes even more compelling for risk-tolerant investors looking for high-reward opportunities in biotech.
The company’s price-to-sales ratio of 3.1× also looks undervalued when compared to sector averages, which often exceed 8× for clinical-stage peers. With revenues already growing more than 240% over the last three years, Spero has demonstrated a trajectory that supports a higher valuation multiple once investor sentiment improves.
Why SPRO is Poised for a Turnaround
The bearish sentiment that pushed SPRO down nearly 18% in recent weeks appears disconnected from the underlying story. The RSI shows the stock is oversold, analysts have dramatically raised EPS forecasts, the company just delivered a major earnings beat, and its lead drug candidate achieved a Phase 3 success that could transform treatment for millions of patients. With a Zacks Rank of #2 (Buy) and Wall Street targets suggesting triple-digit upside, the pieces are in place for a powerful turnaround.
For investors who can stomach volatility, Spero Therapeutics represents a classic biotech rebound opportunity. Its combination of oversold technicals, rising analyst optimism, financial resilience, and groundbreaking clinical progress makes the case for a bullish outlook stronger than ever.
READ ALSO: Exact Sciences (EXAS) Just Made Cancer Detection 100x Easier! and Soleno Therapeutics (SLNO): The Biotech Company That Could Make You Rich.
